Rapport Therapeutics

New Capabilities

Planning two Phase 3 bipolar mania trials from the second half of 2027, with focal onset seizure Phase 3 trials already enrolling

Rapport Therapeutics' epilepsy pill beat placebo in a mid-stage bipolar mania trial, the company said Oct. 20. The 3.1-point gap on a 60-point mania scale was statistically significant, but it missed the four points chief executive Abraham Ceesay had called clinically meaningful.

Updated Oct 26